Algorae Pharmaceuticals Limited (LVCLF)

0.0070 +0.0029 (+70.73%) At close: 02:09PM EDT

Algorae Pharmaceuticals Limited

Rialto South Tower
Level 23 525 Collins Street
Melbourne, VIC 3000
Australia
61 2 9698 5414
https://www.algoraepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David Richard Hainsworth	CEO & Executive Chairman	40.73k	N/A	1973
Dr. Carolyn M. Sue A.M., B.S., Ph.D.	Member of Medical Advisory Board & Chief Medical Officer of NTCELL	8.62k	N/A	1963
Dr. James A. Mckenna	Chief Scientific Officer	N/A	N/A	N/A
Ms. Jennifer Voon	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.

Corporate governance

Algorae Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.